Trovagene

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

Trovagene's Onvansertib Shows Response in Phase Ib AML Study

TrovaGene Inc (NASDAQ: TROV) shares, which had been on a downtrend since early April, reversed course in mid-August.

TrovaGene Shares Volatile Ahead of Oncology Presentation

AbbVie

TrovaGene announced that it had achieved a positive finding using its drug onvansertib in combination with AbbVie's Venclexta in relapsed or refractory AML patients.

TrovaGene Proves Drug Success In Treating AML With Multiple Combinations

It's déjà vu for biotech investors, who witnessed a wild rally in Bio-Path Holdings Inc (NASDAQ: BPTH) this week.

What's Behind TrovaGene's Volatile Ride?

News for Trovagene Stock (TROV)